Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3171019 | 0.98 | DPP7 (0.60) | DPP7CXCR4KMT2ACYP3A4CYP2D6 | |
| SCHEMBL3171946 | 0.97 | DPP7 (0.57) | DPP7CXCR4KMT2ACYP3A4CYP2D6 | |
| SCHEMBL3181062 | 0.92 | CYP2C19 (0.55) | DPP7CXCR4CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3176696 | 0.92 | DPP7 (0.72) | DPP7CXCR4KMT2ACYP3A4CYP2D6 | |
| SCHEMBL3175086 | 0.91 | DPP7 (0.70) | DPP7CXCR4KMT2ACYP3A4CYP2D6 | |
| SCHEMBL3179432 | 0.89 | DPP7 (0.66) | DPP7CXCR4KMT2ACYP3A4CYP2D6 | |
| SCHEMBL3185540 | 0.87 | CYP2C19 (0.67) | DPP7KMT2ACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL14287710 | 0.85 | HRH3 (0.70) | HRH3 | |
| SCHEMBL3165932 | 0.85 | DPP7 (0.82) | DPP7CXCR4KMT2ACYP3A4CYP2D6 | |
| SCHEMBL3175514 | 0.84 | CYP2C19 (0.70) | DPP7KMT2ACYP3A4CYP2D6SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | INSTITUT QUIMIC DE SARRIA CETS (ES) | 2010-01-28 | — | — | US | claimed |
| EP-2100890-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | Institut Quimic De Sarria Cets (ES) | 2009-09-16 | — | — | EP | claimed |
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | INSTITUT QUIMIC DE SARRIA CETS (ES) | 2010-01-28 | — | — | US | disclosed |
| EP-2100890-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | Institut Quimic De Sarria Cets (ES) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | MSR1, CCR5, CD4 | DPP7 4221/4885CXCR4 117/4885KMT2A 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.